Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Recruitment milestone reached in Diamyd® Phase 3 trial

Diamyd Medical’s precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events have been reported, and no patients have discontinued the trial.“This is an important milestone in our Phase 3 trial and the notable zero dropout rate confirms our insights from previous trials regarding the safety and convinience of the treatment,” says Ulf Hannelius, President & CEO of Diamyd Medical. “We are deeply grateful to our participants for their continued commitment to the trial and to the dedicated staff at our participating clinics for

Correction to previous annoucement No 043: WindowMaster narrows the 2024 guidance in the high end of the previous announced range:

Company announcement - No. 044-2024 - Insider InformationVedbaek,12 April 2024Record high order intake for Q1 2024 · Order intake reached a record high level end of Q1 amounted to DKK 74m for Q1 2024 and DKK 268m 12-month-running (2023: DKK 60m for Q1 and DKK 244m 12-month-running). This represents a growth of 24% for the quarter and 10% 12-month-running. The strong growth is coming from all our main markets (except Nordic) and is seen as being able to deliver on the strategy “Accelerate-Core” as it is mainly the project business driving the growth. We also see some improvements from

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 85 – 12 APRIL 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 30/24 and 31/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

BioStock: CLS makes progress in prostate cancer in Europe and the US

Clinical Laserthermia Systems has treated its first prostate cancer patients in Italy and secured additional orders and agreements in the US. In addition, the company has presented initial clinical data from the study at Radboud University Medical Center in the Netherlands.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/cls-makes-progress-in-prostate-cancer-in-europe-and-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Invitation to presentation of Betsson AB’s results for the first quarter of 2024

On Friday, 26 April 2024 at 07:30 CEST, Betsson will publish its interim report for the first quarter of 2024. At 9:00 CEST on the same day, Betsson invites analysts, investors, and media to participate in the presentation of the results.The results will be presented by CEO Pontus Lindwall and CFO Martin Öhman. The presentation will be held in English, followed by a Q&A session. Participants are welcome to join via webcast or phone. Link with information on how to participate in the webcast and telephone conference: https://financialhearings.com/event/49076   For further

Invitation to Saab’s Q1 2024 interim report presentation

Saab’s CEO and President Micael Johansson and CFO and deputy CEO Christian Luiga will present Saab’s interim report for January-March 2024.Date: Friday 26 April at 10:00 a.m. (CET).  The report is published at 07.30 a.m. (CET) the same day at www.saab.com. You are welcome to watch the live webcast or dial in to the conference call. It is possible to submit questions over the conference call and from the webcast page. Live webcast: www.saab.com/investors/webcast/q1-2024  Registration for conference call: www.saab.com/investors/conference-call-Q1 The interim report,

BioStock: Respiratorius’ US patent application reopens

After the initial rejection of Respiratorius’ patent application, the US Patent and Trademark Office’s Patent Trial and Appeal Board has now sided with the company. The decision means a reopening of the application regarding the oral formulation of VAL001. BioStock has contacted CEO Johan Drott to gain a better understanding of what this implies for the project.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/respiratorius-us-patent-application-reopens/ This is a press release from BioStock - Connecting Innovation & Capital. https:/

Odfjell introduces an innovative transition finance framework

Odfjell has passed another significant milestone on its transition journey with the introduction of a ‘Transition Finance Framework’. The initiative is a first in the Nordic region and solidifies the shipping company’s position at the forefront of sustainable finance practices.Odfjell has worked actively to reduce emissions for more than a decade. This work has led to documented results, positioning the chemical tanker operator as a sustainability leader in the international shipping industry. The company is now taking another proactive step toward reaching its ambitious climate targets by

BoMill Q1 Report January – March 2024

BoMill AB (”BoMill” or the “Company”) hereby publishes the Interim Report for the period January 1 – March 31, 2024. The Report is available as an attached file to this release and on BoMill’s website. Below is a summary of the report.POSITIVE START OF 2024 WITH NEW ORDERS CEO Andreas Jeppsson comments: “2024 has started very well for BoMill InSight™ with our agreement with Lantmännen and the repeat order from Baltijos Javai to increase capacity. I’m confident we are on the right track for success.” Net sales and income for the first quarter (January – March 2024)        · Net

Dicot in preparation for clinical phase 2a trial

Press release: Uppsala, Sweden, April 12, 2024. The pharmaceutical company Dicot, which recently announced that a reporting from the last part of the phase 1 study will be published at the end of April, is in parallel preparing for a clinical phase 2a trial with its potency drug candidate. Today, the company can announce that a partner has been contracted to conduct the trial and that the study drug has been produced by Thermo Fisher Scientific, the contracted manufacturer.Dicot will soon report the results from the last part in the clinical phase 1 study. In parallel, preparatory

Indutrade acquires the geotechnical monitoring specialist Geosense

Indutrade has signed an agreement to acquire all shares in the British company Geosense Ltd., www.geosense.co.uk, with annual sales of approximately GBP 9 million (SEK 120 million). Geosense is a leading manufacturer that offers a broad range of geotechnical solutions to the infrastructure, construction and mining industries. The product offering consists of instruments and sensors that measure tilt, pressure, load, displacement and temperature along with automated data acquisition systems to complement its sensors. The company’s products are used globally in major infrastructure

Elisabeth Hedman appointed as new CFO and Head of IR at Sleep Cycle

Gothenburg, 12 April, 2024. Sleep Cycle AB (publ), a global leader in AI-driven sleep analysis, announces today the appointment of Elisabeth Hedman as the new Chief Financial Officer (CFO) and Head of Investor Relations (IR) effective June 1. Elisabeth joins Sleep Cycle from her role as CFO at TimeEdit and brings with her a wealth of experience from previous positions at TimeEdit and Norion Bank."We are thrilled to welcome Elisabeth Hedman to Sleep Cycle as our new CFO and Head of IR. Her track record of spearheading financial operations and catalyzing growth not only demonstrates her

Notice of Annual General Meeting in Epiroc AB

Stockholm, Sweden: Epiroc AB is hereby convening an Annual General Meeting to be held on Tuesday May 14, 2024, at 4.00 p.m. (CEST) at Filmstaden Sickla, Sickla köpkvarter, Marcusplatsen 19, Nacka, Sweden. Registration starts at 3.30 p.m. Coffee will be served from 2.00 p.m.Please see the full Notice below, in attached pdf, or visit www.epirocgroup.com/agm.For more information please contact:Karin Larsson, VP Investor Relations and Media+46 10 755 0106ir@epiroc.comOla Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.com Epiroc is a global productivity partner

The subscription price for the warrants of series TO4 in Wyld Networks AB has been determined to SEK 1.83 and the subscription period starts April 15, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.During the third quarter of 2023, Wyld Networks AB (“Wyld Networks” or the “Company”) entered a loan agreement and conducted a directed issue and a rights issue. In

White Pearl Technology Group today announces it has signed a new service contract with a major local government authority in South Africa.

White Pearl Technology Group today announces it has signed a new service contract with a major local government authority in South Africa.The contract, for IT Implementation and Support Services, commences immediately and is for a term of two years.The value of the contract is approximately USD11M (118 MSEK) over the two-year term of the project and will begin to be reflected in WPTG’s Q2 results. This deal marks a major milestone in the development of WPTG’s business and ensures that the strong  growth rate is maintained in the coming years. This information is such that White Pearl

Invitation to conference call Byggmax Group's Interim Report January 1 – March 31, 2024

Byggmax Group's Interm Report for the first quarter 2024 will be published on Tuesday April 23, at approximately 08.00 CET. A conference call will be held on the same day, in English, at 10.30 CET.Byggmax Group's CEO Karl Sandlund and CFO Helena Nathhorst will present the results for the first quarter 2024 and answer questions. The presentation will be available from 08.30 CET on April 23, at https://om.byggmax.se under Investors / Presentations. To join the conference call the following numbers: SE (Toll Free): +46 20 012 37 17SE (Local): +46 10 884 80 16UK (Toll Free): +44

Publication of Annual Report for 2023

Oslo, 12 April 2024: BlueNord ASA ("BlueNord" or the "Company") has today published the Annual Report for 2023. In addition, the Company's 2023 Annual Report in European Single Electronic Format (ESEF) is attached. The reports will be made available at the Company's website: www.bluenord.com.  This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.  *** Contact:Cathrine Torgersen, Chief Operating OfficerPhone: +47 915 28 501Email: cathrine.torgersen@bluenord.com

Norse Atlantic ASA secures USD 20 million liquidity buffer by shareholder loan

Arendal, Norway, 12 April 2024: Norse Atlantic ASA (the "Company" or "Norse") has secured a USD 20 million revolving credit facility (the "Facility") from its two largest shareholders Scorpio Holdings Limited and B T Larsen & Co Limited, currently holding 21.22% and 18.88% of the Company's issued shares, respectively. B T Larsen & Co Limited is ultimately controlled by Bjørn Tore Larsen, CEO of Norse. The Facility demonstrates the continuing strong support the Company has from its two largest shareholders. The Facility will provide Norse with a liquidity buffer prior to moving into the

Net Asset Value(s)

RIZE SUSTAINABLE FUTURE OF FOOD UCITS ETF (LEI: 635400XEUXEEYJDGAN37) Final Net Asset Value FUND NAME NAV ISIN NAV DATE RIZE SUSTAINABLE 3.9699 USD IE00BLRPQH01 11 April 2024FUTURE OF FOOD UCITS ETF RIZE CYBER SECURITY AND DATA PRIVACY UCITS ETF (LEI: 635400X9AIBDQQ6PQR51) Final Net Asset Value FUND NAME NAV­ ISIN NAV DATERIZE CYBER SECURITY AND 7.3781 USD IE00BJXRZJ40 11 April 2024DATA PRIVACY UCITS ETF RIZE DIGITAL PAY ECONOMY ETF (LEI: LEI 635400LYAWYIKLU7RN49) Final

STOREBRAND ASA: Minor adjustment to group reporting

In connection with the release of the results for Q1 2024, Storebrand will implement a minor adjustment to its alternative income statement. In historical reporting, performance-related cost in the asset management business was recognised continuously, while performance-related income was fully recognised in the 4th quarter. Starting from the 1st quarter of 2024, Storebrand will record performance-related income on continuous basis to align the timing of performance-related income and costs. This change will not impact the annual result. The adjustment will reduce the complexity in

There are no items matching the current filter
There are no more items matching the current filter
Back to top